Literature DB >> 20372106

Transduction of human primitive repopulating hematopoietic cells with lentiviral vectors pseudotyped with various envelope proteins.

Yoon-Sang Kim1, Matthew M Wielgosz, Phillip Hargrove, Steven Kepes, John Gray, Derek A Persons, Arthur W Nienhuis.   

Abstract

Lentiviral vectors are useful for transducing primitive hematopoietic cells. We examined four envelope proteins for their ability to mediate lentiviral transduction of mobilized human CD34(+) peripheral blood cells. Lentiviral particles encoding green fluorescent protein (GFP) were pseudotyped with the vesicular stomatitis virus envelope glycoprotein (VSV-G), the amphotropic (AMPHO) murine leukemia virus envelope protein, the endogenous feline leukemia viral envelope protein or the feline leukemia virus type C envelope protein. Because the relative amount of genome RNA per ml was similar for each pseudotype, we transduced CD34(+) cells with a fixed volume of each vector preparation. Following an overnight transduction, CD34(+) cells were transplanted into immunodeficient mice which were sacrificed 12 weeks later. The average percentages of engrafted human CD45(+) cells in total bone marrow were comparable to that of the control, mock-transduced group (37-45%). Lenti-particles pseudotyped with the VSV-G envelope protein transduced engrafting cells two- to tenfold better than particles pseudotyped with any of the gamma-retroviral envelope proteins. There was no correlation between receptor mRNA levels for the gamma-retroviral vectors and transduction efficiency of primitive hematopoietic cells. These results support the use of the VSV-G envelope protein for the development of lentiviral producer cell lines for manufacture of clinical-grade vector.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20372106      PMCID: PMC2911247          DOI: 10.1038/mt.2010.48

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  51 in total

1.  Correction of murine sickle cell disease using gamma-globin lentiviral vectors to mediate high-level expression of fetal hemoglobin.

Authors:  Tamara I Pestina; Phillip W Hargrove; Dennis Jay; John T Gray; Kelli M Boyd; Derek A Persons
Journal:  Mol Ther       Date:  2008-12-02       Impact factor: 11.454

Review 2.  Stem cell engineering for the treatment of severe hemoglobinopathies.

Authors:  Michel Sadelain; Farid Boulad; Leszek Lisowki; Paolo Moi; Isabelle Riviere
Journal:  Curr Mol Med       Date:  2008-11       Impact factor: 2.222

3.  Efficient gene transfer into rhesus repopulating hematopoietic stem cells using a simian immunodeficiency virus-based lentiviral vector system.

Authors:  Hideki Hanawa; Peiman Hematti; Keyvan Keyvanfar; Mark E Metzger; Allen Krouse; Robert E Donahue; Steve Kepes; John Gray; Cynthia E Dunbar; Derek A Persons; Arthur W Nienhuis
Journal:  Blood       Date:  2004-02-19       Impact factor: 22.113

4.  Efficient construction of producer cell lines for a SIN lentiviral vector for SCID-X1 gene therapy by concatemeric array transfection.

Authors:  Robert E Throm; Annastasia A Ouma; Sheng Zhou; Anantharaman Chandrasekaran; Timothy Lockey; Michael Greene; Suk See De Ravin; Morvarid Moayeri; Harry L Malech; Brian P Sorrentino; John T Gray
Journal:  Blood       Date:  2009-03-13       Impact factor: 22.113

5.  Inhibition of VSV binding and infectivity by phosphatidylserine: is phosphatidylserine a VSV-binding site?

Authors:  R Schlegel; T S Tralka; M C Willingham; I Pastan
Journal:  Cell       Date:  1983-02       Impact factor: 41.582

6.  Phosphatidylserine is not the cell surface receptor for vesicular stomatitis virus.

Authors:  David A Coil; A Dusty Miller
Journal:  J Virol       Date:  2004-10       Impact factor: 5.103

7.  Passage through mitosis is required for oncoretroviruses but not for the human immunodeficiency virus.

Authors:  P F Lewis; M Emerman
Journal:  J Virol       Date:  1994-01       Impact factor: 5.103

8.  In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector.

Authors:  L Naldini; U Blömer; P Gallay; D Ory; R Mulligan; F H Gage; I M Verma; D Trono
Journal:  Science       Date:  1996-04-12       Impact factor: 47.728

9.  Neutralized vesicular stomatitis virus binds to host cells by a different "receptor".

Authors:  R Schlegel; M Wade
Journal:  Biochem Biophys Res Commun       Date:  1983-07-29       Impact factor: 3.575

10.  Sustained high-level polyclonal hematopoietic marking and transgene expression 4 years after autologous transplantation of rhesus macaques with SIV lentiviral vector-transduced CD34+ cells.

Authors:  Yoo-Jin Kim; Yoon-Sang Kim; Andre Larochelle; Gabriel Renaud; Tyra G Wolfsberg; Rima Adler; Robert E Donahue; Peiman Hematti; Bum-Kee Hong; Jean Roayaei; Keiko Akagi; Janice M Riberdy; Arthur W Nienhuis; Cynthia E Dunbar; Derek A Persons
Journal:  Blood       Date:  2009-04-01       Impact factor: 22.113

View more
  13 in total

1.  RD2-MolPack-Chim3, a packaging cell line for stable production of lentiviral vectors for anti-HIV gene therapy.

Authors:  Anna Stornaiuolo; Bianca Maria Piovani; Sergio Bossi; Eleonora Zucchelli; Stefano Corna; Francesca Salvatori; Fulvio Mavilio; Claudio Bordignon; Gian Paolo Rizzardi; Chiara Bovolenta
Journal:  Hum Gene Ther Methods       Date:  2013-08-03       Impact factor: 2.396

2.  Development of Rous sarcoma Virus-like Particles Displaying hCC49 scFv for Specific Targeted Drug Delivery to Human Colon Carcinoma Cells.

Authors:  Tatsuya Kato; Megumi Yui; Vipin Kumar Deo; Enoch Y Park
Journal:  Pharm Res       Date:  2015-06-06       Impact factor: 4.200

Review 3.  Development of gene therapy for thalassemia.

Authors:  Arthur W Nienhuis; Derek A Persons
Journal:  Cold Spring Harb Perspect Med       Date:  2012-11-01       Impact factor: 6.915

4.  High-efficiency transduction of rhesus hematopoietic repopulating cells by a modified HIV1-based lentiviral vector.

Authors:  Naoya Uchida; Phillip W Hargrove; Coen J Lap; Molly E Evans; Oswald Phang; Aylin C Bonifacino; Allen E Krouse; Mark E Metzger; Anh-Dao Nguyen; Matthew M Hsieh; Tyra G Wolfsberg; Robert E Donahue; Derek A Persons; John F Tisdale
Journal:  Mol Ther       Date:  2012-08-07       Impact factor: 11.454

5.  Specific gene transfer to neurons, endothelial cells and hematopoietic progenitors with lentiviral vectors.

Authors:  Brigitte Anliker; Tobias Abel; Sabrina Kneissl; Juraj Hlavaty; Antonio Caputi; Julia Brynza; Irene C Schneider; Robert C Münch; Helga Petznek; Roland E Kontermann; Ulrike Koehl; Ian C D Johnston; Kari Keinänen; Ulrike C Müller; Christine Hohenadl; Hannah Monyer; Klaus Cichutek; Christian J Buchholz
Journal:  Nat Methods       Date:  2010-10-10       Impact factor: 28.547

6.  Transduction of human CD34+ repopulating cells with a self-inactivating lentiviral vector for SCID-X1 produced at clinical scale by a stable cell line.

Authors:  Michael R Greene; Timothy Lockey; Perdeep K Mehta; Yoon-Sang Kim; Paul W Eldridge; John T Gray; Brian P Sorrentino
Journal:  Hum Gene Ther Methods       Date:  2012-11-07       Impact factor: 2.396

7.  Comparison of insulators and promoters for expression of the Wiskott-Aldrich syndrome protein using lentiviral vectors.

Authors:  Rachel M Koldej; Gael Carney; Matthew M Wielgosz; Sheng Zhou; Jun Zhan; Brian P Sorrentino; Arthur W Nienhuis
Journal:  Hum Gene Ther Clin Dev       Date:  2013-06-20       Impact factor: 5.032

8.  The Ongoing Challenge of Hematopoietic Stem Cell-Based Gene Therapy for β-Thalassemia.

Authors:  Ekati Drakopoulou; Eleni Papanikolaou; Nicholas P Anagnou
Journal:  Stem Cells Int       Date:  2011-11-13       Impact factor: 5.443

9.  Generation of a lentiviral vector producer cell clone for human Wiskott-Aldrich syndrome gene therapy.

Authors:  Matthew M Wielgosz; Yoon-Sang Kim; Gael G Carney; Jun Zhan; Muralidhar Reddivari; Terry Coop; Richard J Heath; Scott A Brown; Arthur W Nienhuis
Journal:  Mol Ther Methods Clin Dev       Date:  2015-01-21       Impact factor: 6.698

10.  RD-MolPack technology for the constitutive production of self-inactivating lentiviral vectors pseudotyped with the nontoxic RD114-TR envelope.

Authors:  Virna Marin; Anna Stornaiuolo; Claudia Piovan; Stefano Corna; Sergio Bossi; Monika Pema; Erica Giuliani; Cinzia Scavullo; Eleonora Zucchelli; Claudio Bordignon; Gian Paolo Rizzardi; Chiara Bovolenta
Journal:  Mol Ther Methods Clin Dev       Date:  2016-05-11       Impact factor: 6.698

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.